The division has a nationally recognized fellowship program designed to train specialist pediatricians seeking a career in academic pediatric hematology/oncology. Since our faculty has considerable strength in clinical and basic investigation, the program is well suited to candidates interested in both tracks. The program strives to not only make the trainee highly skilled in clinical care, but also capable of designing and performing sophisticated biomedical investigation that focuses on understanding and treating the childhood diseases as broadly defined by our specialty.
In order to train physicians appropriately for careers in this field, the fellowship lasts "three-plus" years. The first-year fellow has strictly clinical responsibilities with every third week on call from home. In addition to six months as supervisor of the in-house clinical service, the fellow rotates on electives in laboratories such as coagulation/blood bank, HLA lab, cyogenetics, molecular diagnostics and clinical services including radiation therapy, pathology, pheresis, adult hematology and bone marrow transplant. This broad curriculum provides a strong foundation for the fellow ensuring that he or she is well equipped with an extensive and sophisticated fund of knowledge.
After the first year, the fellow begins an individualized program of clinical or basic science investigation mentored by a faculty investigator at the School of Medicine. During this period, the trainee is expected to develop the knowledge, thought processes and laboratory skills necessary to develop into an independent, competitive investigator in today's scientific community. In order to focus on his or her investigation, the fellow's clinical responsibilities are limited to attending one clinic day each week and two clinical conferences.
The program has a long history of developing successful physician
investigators. Our fellows have published numerous articles in highly
competitive areas of biomedical research, and they continue to maintain a
history of success in acquiring extramural funding support. Thus, fellows who
graduate from our program can be confident that they will meet the challenges
they will face as they advance through their academic careers.
1.
Blunt AG, Lawshe
A, Cunningham ML, et al: Overlapping expression and redundant activation of
mesenchymal fibroblast growth factor (FGF) receptors by alternatively
spliced FGF-8 ligands. Journal of Biological Chemistry 272:3733-8,
1997.
2.
Boudreaux JM,
Towler DA: Synergistic induction of osteocalcin gene expression:
identification of a bipartite element conferring fibroblast growth factor 2
and cyclic AMP responsiveness in the rat osteocalcin promoter. Journal of
Biological Chemistry 271:7508-15, 1996.
3.
Brandt JM,
Djouadi F, Kelly DP: Fatty acids activate transcription of the muscle
carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome
proliferator-activated receptor alpha. Journal of Biological Chemistry
273:23786-92, 1998.
4.
Crawford DF,
Piwnica-Worms H: The G(2) DNA damage checkpoint delays expression of genes
encoding mitotic regulators. Journal of Biological Chemistry
276:37166-37177, 2001.
5.
DeBaun MR,
Glauser TA, Siegel M, et al: Noninvasive central nervous system imaging in
sickle cell anemia. A preliminary study comparing transcranial Doppler with
magnetic resonance angiography. Journal of Pediatric Hematology/Oncology
17:29-33, 1995.
6.
DeBaun MR, Brown
M, Kessler L: Screening for Wilms' tumor in children with high-risk
congenital syndromes: considerations for an intervention trial. Medical &
Pediatric Oncology 27:415-21, 1996.
7.
Djouadi F, Brandt JM, Weinheimer CJ, et al: The role of the
peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control
of cardiac lipid metabolism. Prostaglandins Leukotrienes & Essential
Fatty Acids 60:339-43, 1999.
8.
Frei-Jones MJ BA, Rogers ZR,
Buchanan GR. Vaso-occlusive episodes in older children with sickle cell
disease: emergency department management and pain assessment. J Peds 2007;
In press.
9.
Gauvain KM,
McKinstry RC, Mukherjee P, et al: Evaluating pediatric brain tumor
cellularity with diffusion-tensor imaging. AJR. American Journal of
Roentgenology 177:449-54, 2001.
10.
Gomperts BN,
Gong-Cooper X, Hackett BP: Foxj1 regulates basal body anchoring to the
cytoskeleton of ciliated pulmonary epithelial cells. Journal of Cell
Science 117:1329-37, 1329.
11.
Grossman WJ,
Verbsky JW, Barchet W, et al: Human T regulatory cells can use the perforin
pathway to cause autologous target cell death. Immunity 21:589-601,
2004.
12.
Grossman WJ,
Verbsky JW, Tollefsen BL, et al: Differential expression of granzymes A and
B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood
104:2840-8, 2004.
13.
Hanson R.D., Hess
JL, Yu BD, et al: Mammalian Trithorax and polycomb-group homologues are
antagonistic regulators of homeotic development. Proceedings of the National Academy
of Sciences of the United States of America 96:14372-7, 1999.
14.
Herron S, Bacak SJ, King A, et al: Inadequate recognition of
education resources required for high-risk students with sickle cell
disease. Archives of Pediatrics & Adolescent Medicine. 157:104, 2003.
15.
Hulbert
ML. Scothorn DJ. Panepinto JA. Scott JP. Buchanan GR. Sarnaik S. Fallon R.
Chu JY. Wang W. Casella JF. Resar L. Berman B. Adamkiewicz T. Hsu LL.
Smith-Whitley K. Mahoney D. Woods G. Watanabe M. DeBaun MR.
Exchange blood
transfusion compared with simple transfusion for first overt stroke is
associated with a lower risk of subsequent stroke: a retrospective cohort
study of 137 children with sickle cell anemia
Journal of Pediatrics. 149(5):710-2, 2006 Nov.
16.
Kelly ME, Chan
AC: Regulation of B cell function by linker proteins. Current Opinion in
Immunology 12:267-75, 2000.
17.
King AA, Tang
S, Ferguson KL, et al: An education program to increase teacher knowledge
about sickle cell disease. Journal of School Health 75:11-4, 2005.
18.
Link DC, Kunter G, Kasai
Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC,
Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellannι-Chantelot C,
Vardiman JW, Caligiuri MA, Bloomfield CA, DiPersio JF, Tomasson MH, Graubert
TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, and Ley
TJ.
Distinct patterns of mutations occurring in de novo
AML versus AML arising in the setting of severe congenital neutropenia.
Blood, Sep 2007; 110: 1648
- 1655.
19.
Luchtman-Jones L,
Broze GJ: The current status of coagulation. Annals of Medicine
27:47-52, 1995.
20.
Mascotti DP, Rup D, Thach RE: Regulation of iron metabolism:
translational effects mediated by iron, heme, and cytokines. Annual
Review of Nutrition 15:239-61, 1995.
21.
Mascotti DP, Goessling LS, Rup D, et al: Effects of the
ferritin open reading frame on translational induction by iron. Progress
in Nucleic Acid Research & Molecular Biology 55:121-34, 1996.
22.
McLemore ML, Grewal S, Liu F, et al: STAT-3 activation is
required for normal G-CSF-dependent proliferation and granulocytic
differentiation. Immunity 14:193-204, 2001.
23.
Newberry EP, Boudreaux JM, Towler DA: The rat osteocalcin
fibroblast growth factor (FGF)-responsive element: an okadaic
acid-sensitive, FGF-selective transcriptional response motif. Molecular
Endocrinology 10:1029-40, 1996.
24.
Rao
A. Kamani N. Filipovich A. Lee SM. Davies SM. Dalal J.
Shenoy S.
Successful bone marrow transplantation for IPEX syndrome after
reduced-intensity conditioning. Blood.
109(1):383-5, 2007 Jan 1.
25.
Richards MK,
Liu F, Iwasaki H, et al: Pivotal role of granulocyte colony-stimulating
factor in the development of progenitors in the common myeloid pathway.Blood
102:3562-8, 2003.
26.
Saylors RL, 3rd,
Sidransky D, Friedman HS, et al: Infrequent p53 gene mutations in
medulloblastomas. Cancer Research 51:4721-3, 1991.
27.
Schaefer A,
Jasinski M, Bessler M: High-dose cyclophosphamide does not eradicate
paroxysmal nocturnal haemoglobinuria haematopoiesis in mice carrying a Piga
gene mutation. British Journal of Haematology. 120:903-6, 2003.
28.
Wasson JC, Saylors RL, 3rd, Zeltzer P, et al: Oncogene
amplification in pediatric brain tumors. Cancer Research 50:2987-90,
1990.
29.
Yamaguchi Y, Heiny ME, Shimizu N, et al: Expression of the Wilson disease gene is
deficient in the Long-Evans Cinnamon rat. Biochemical Journal
301:1-4, 1994.
30.
Yamaguchi Y, Heiny ME, Suzuki M, et al: Biochemical
characterization and intracellular localization of the Menkes disease
protein. Proceedings of the National
Academy
of Sciences of the United
States of America 93:14030-5, 1996.
31.
Yang E, Zha J,
Jockel J, et al: Bad, a heterodimeric partner for Bcl-XL and Bcl-2,
displaces Bax and promotes cell death. Cell 80:285-91, 1995.
32.
Yu BD, Hanson R.D., Hess JL, et al: MLL, a mammalian
trithorax-group gene, functions as a transcriptional maintenance factor in
morphogenesis. Proceedings of the
National
Academy of Sciences of the
United States of America 95:10632-6, 1998.
33.
Zha J, Harada H, Yang E, et al: Serine phosphorylation of
death agonist BAD in response to survival factor results in binding to
14-3-3 not BCL-X(L). Cell 87:619-28, 1996.
or
TOP
Robert J. Hayashi, M.D.
C/O Peg Greco Schneider, Fellowship Administrator
Division of Hematology/Oncology
Department of Pediatrics
Washington University School of Medicine
660 S. Euclid Ave. Box 8116
St. Louis, MO 63110
(314) 454-4327 (Voice)
(314) 454-4283 (Fax)
SCHOOL OF MEDICINE
